Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
17,600
ISIN
US3755581036
Website
Gilead Sciences Metrics
BasicAdvanced
$137B
23.35
$4.73
0.28
$3.10
2.86%
Price and volume
Market cap
$137B
Beta
0.28
52-week high
$119.96
52-week low
$62.69
Average daily volume
9.1M
Dividend rate
$3.10
Financial strength
Current ratio
1.369
Quick ratio
0.998
Long term debt to equity
131.104
Total debt to equity
130.789
Dividend payout ratio (TTM)
82.45%
Interest coverage (TTM)
11.01%
Management effectiveness
Return on assets (TTM)
12.00%
Return on equity (TTM)
32.66%
Valuation
Price to earnings (TTM)
23.35
Price to revenue (TTM)
4.793
Price to book
7.21
Price to tangible book (TTM)
-16.17
Price to free cash flow (TTM)
13.99
Dividend yield (TTM)
2.81%
Forward dividend yield
2.86%
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
1,118.07%
3-year revenue growth (CAGR)
1.51%
3-year earnings per share growth (CAGR)
9.74%
3-year dividend per share growth (CAGR)
2.72%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Benzinga·22 hours ago
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
CNBC·3 days ago
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
Business Wire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun13
Gilead Sciences
Dividend·Ex-dividend
Jun27
Gilead Sciences
Dividend·Payment
$0.79Per share
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $137B as of June 06, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 23.35 as of June 06, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of June 06, 2025, the dividend rate is $3.1 and the yield is 2.86%. Gilead Sciences has a payout ratio of 82.45% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for June 27, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.